ep·ro·sar·tan

(ĕp′rō-sär′tăn)

An angiotensin II receptor blocker drug, C₂₃H₂₄N₂O₄S, used in its mesylate form to treat hypertension.

[Perhaps E-, stereochemical pref. + pro(panoic acid) + -sartan, angiotensin II receptor blocker suff.; see losartan.]

American Heritage® Dictionary of the English Language, Fifth Edition. Copyright © 2016 by Houghton Mifflin Harcourt Publishing Company. Published by Houghton Mifflin Harcourt Publishing Company. All rights reserved.

References in periodicals archive

28 December 2011 - US generic and specialty pharmaceutical major Mylan Inc (NASDAQ:MYL) said on Tuesday its Mylan Pharmaceuticals Inc unit had obtained final US Food and Drug Administration (FDA) approval for its ANDA for Eprosartan Mesylate Tablets, 400 mg (base) and 600 mg (base), the generic version of Abbott's (NYSE:ABT) hypertension treatment Teveten Tablets.

Mylan gains final FDA nod for generic version of high blood pressure drug Teveten Tablets

Teveten(R) HCT is a combination of the angiotensin II receptor blocker (ARB), eprosartan mesylate, and the diuretic, hydrochlorothiazide.

FDA APPROVES BIOVAIL'S TEVETEN HCT FOR HYPERTENSION

Unimed currently markets Teveten(R) (eprosartan mesylate) for the treatment of hypertension, Marinol (dronabinol) as an appetite stimulant for people living with HIV disease and as an antiemetic for people with cancer, Anadrol(R)-50 (oxymetholone) for the treatment of various anemias, and Maxaquin(R) (lomefloxacin HCl), a broad-spectrum quinolone antibiotic, for both complicated and uncomplicated urinary tract infections.

FDA APPROVES ANDROGEL TO TREAT MALE TESTOSTERONE DEFICIENCY

All content on this website, including dictionary, thesaurus, literature, geography, and other reference data is for informational purposes only. This information should not be considered complete, up to date, and is not intended to be used in place of a visit, consultation, or advice of a legal, medical, or any other professional.